FDA shares 5-year blueprint for designing more structured risk-benefit analysis

President Biden Issues Executive Order Requiring COVID-19 Safeguards for US Government Prime Contractors and Subcontractors

New Developments in China’s Drug Change Management Regulations

FDA Seeks Comments on Transition of Certain Drugs to Device Status Following Genus DC Circuit Decision